| Product Name | NAGA, 18-411aa, Human, Baculovirus |
|---|---|
| Description | NAGA, also known as alpha-N-acetylgalactosaminidase, is a lysosomal exoglycosidase that cleaves terminal alpha-N-acetylgalactosamine residues from glycopeptides and glycolipids. It is hardly expected to cause an allergic reaction in Fabry disease patients. It is highly promising as a new and safe enzyme for ERT for Fabry disease. Recombinant human NAGA, fused to His-tag at C-terminus, was expressed in insect cell and purified by using conventional chromatography techniques. |
| Synonyms | Alpha-N-acetylgalactosaminidase, NAGA, D22S674, GALB,Acetylgalactosaminidase, alpha N (alpha galactosidase B), Alpha galactosidase B, Alpha N acetylgalactosaminidase, N acetylgalactosaminidase, alpha |
| Host | Virus |
| Molecular Weight | 14.5kDa (127aa) confirmed by MALDI-TOF |
| Amino Acid Sequence | LDNGLLQTPP MGWLAWERFR CNINCDEDPK NCISEQLFME MADRMAQDGW RDMGYTYLNI DDCWIGGRDA SGRLMPDPKR FPHGIPFLAD YVHSLGLKLG IYADMGNFTC MGYPGTTLDK VVQDAQTFAE WKVDMLKLDG CFSTPEERAQ GYPKMAAALN ATGRPIAFSC SWPAYEGGLP PRVNYSLLAD ICNLWRNYDD IQDSWWSVLS ILNWFVEHQD ILQPVAGPGH WNDPDMLLIG NFGLSLEQSR AQMALWTVLA APLLMSTDLR TISAQNMDIL QNPLMIKINQ DPLGIQGRRI HKEKSLIEVY MRPLSNKASA LVFFSCRTDM PYRYHSSLGQ LNFTGSVIYE AQDVYSGDII SGLRDETNFT VIINPSGVVM WYLYPIKNLE MSQQHHHHHH |
| Tag | His-tag |
| Reactivity | Human |
| Applications | SDS-PAGE |
| Form | Liquid, in 20mM Tris-HCl (pH 8.0) containing 10% glycerol, 0.1M NaCl |
| Concentration | 1mg/ml (determined by Bradford assay) |
| Purity | > 90% by SDS-PAGE. |
| Storage | Can be stored at +4C short term (1-2 weeks). For long term storage, aliquot and store at -2°C or -7°C. Avoid repeated freezing and thawing cycles. |
| References | Clark NE., et al. (2009) J Mol Biol. 393:435-447. Tajima Y., et al. (2009) Am J Hum Genet. 85:569-580. |
| Background | NAGA, also known as alpha-N-acetylgalactosaminidase, is a lysosomal exoglycosidase that cleaves terminal alpha-N-acetylgalactosamine residues from glycopeptides and glycolipids. It is hardly expected to cause an allergic reaction in Fabry disease patients. It is highly promising as a new and safe enzyme for ERT for Fabry disease. Recombinant human NAGA, fused to His-tag at C-terminus, was expressed in insect cell and purified by using conventional chromatography techniques. |
| Supplier | ARP |
All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
